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BackgroundThe Natural History and Neuroprotection in Parkinson Plus Syndromes
(NNIPPS) study was a large phase III randomized placebo-controlled trial of riluzole
in Progressive Supranuclear Palsy (PSP, n = 362) and Multiple System Atrophy (MSA,
n = 398). To assess disease severity and progression, we constructed and validated a
new clinical rating scale as an ancillary study. Methods and Findings Patients were
assessed at entry and 6-montly for up to 3 years. Evaluation of the scale's
psychometric properties included reliability (n = 116), validity (n = 760), and
responsiveness (n = 642). Among the 85 items of the initial scale, factor analysis
revealed 83 items contributing to 15 clinically relevant dimensions, including Activity
of daily Living/Mobility, Axial bradykinesia, Limb bradykinesia, Rigidity, Oculomotor,
Cerebellar, Bulbar/Pseudo-bulbar, Mental, Orthostatic, Urinary, Limb dystonia, Axial
dystonia, Pyramidal, Myoclonus and Tremor. All but the Pyramidal dimension
demonstrated good internal consistency (Cronbach α≥0.70). Inter-rater reliability
was high for the total score (Intra-class coefficient = 0.94) and 9 dimensions (Intra-
class coefficient = 0.80–0.93), and moderate (Intra-class coefficient = 0.54–0.77) for 6.
Correlations of the total score with other clinical measures of severity were good
(rho≥0.70). The total score was significantly and linearly related to survival
(p<0.0001). Responsiveness expressed as the Standardized Response Mean was high
for the total score slope of change (SRM = 1.10), though higher in PSP (SRM = 1.25)
than in MSA (SRM = 1.0), indicating a more rapid progression of PSP. The slope of
change was constant with increasing disease severity demonstrating good linearity of
the scale throughout disease stages. Although MSA and PSP differed quantitatively
on the total score at entry and on rate of progression, the relative contribution of
clinical dimensions to overall severity and progression was similar. Conclusions The
NNIPPS-PPS has suitable validity, is reliable and sensitive, and therefore is
appropriate for use in clinical studies with PSP or MSA.
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